web stats
Track your comments!
[x]


If you registered, comments on your articles and replies to your comments appear here!

Sign in to your account
[x]

Not a Scientific Blogging member yet?

Register Now for a Free Scientificblogging.com Account

  • Customize your profile with pictures, banner, a blogroll and more.
  • Leave comments on articles, add other members to your friend lists, chat with people on the site.
  • Write blog posts that can be seen by hundreds of thousands of readers.

It's free and it only takes a minute!

Already a Scientific Blogging member?

Sign In Now

Aleksandr's Recommended Blogs
[x]
hasn't added any blog recommendations yet.
1
Blogs Instructions
Aleksandr's Recommended Books
[x]
hasn't added any book recommendations yet.
1
Books Instructions
Aleksandr's Affiliates and Organizations
[x]
hasn't added any organizations or groups yet.
1
Badges Instructions
Add Aleksandr Kavokin to your friends
[x]
User picture for rdoctor
Add Aleksandr
Cancel
Fake Banner
About Aleksandr

Aleksandr Kavokin, MD, PhD. Aleksandr received his MD from Russian State Medical University, then did his PhD in Immunology and Allergy. Later (full bio)

By Aleksandr Kavokin | January 29th 2007 02:00 AM | 1 comment
Measles deaths have fallen by 60% worldwide since 1999 -- a major public health success. This exceeds the United Nations goal to halve measles deaths between 1999 and 2005 and is largely due to an unprecedented decline in measles deaths in the African region. The progress was announced today by partners in the Measles Initiative: the American Red Cross, the United States Centers for Disease Control and Prevention (CDC), the United Nations Foundation, UNICEF and the World Health Organization (WHO).


Bangladesh immunizes over 33 million children against measles. (Image courtesy of WHO / Hayatee Hasan)

By Aleksandr Kavokin | January 26th 2007 05:30 AM | 0 comments

As you probably know ulcerative colitis affects around  half a million Americans.



Today in press releases: The U.S. Food and Drug Administration (FDA) has granted approval for LIALDA™ (mesalamine) with MMX® technology for the induction of remission in patients with active, mild to moderate ulcerative colitis.

If you do not know much about the disease, here is the information: